Last updated: October 12, 2026
Cosmetic documentation serves different decisions: a COA records batch or sample test results, an SDS communicates chemical hazards and handling precautions, an ingredient declaration supports product labelling, and an EU PIF holds the required product dossier. A beauty brand needs a package matched to its market, product and supply-chain role; none of these documents replaces the others.
Quick Answer
Request documents by the decision they support. For a production shipment, identify the applicable batch results and release records. Before approving artwork, reconcile the ingredient declaration with the formula and destination-market rules. For chemical handling, assess SDS applicability. For an EU launch, establish the responsible person and complete the product safety dossier.
This is an operational overview, not product-specific legal advice. Sources were checked on October 12, 2026. The procurement checkpoints below are practical recommendations; statutory duties depend on the applicable jurisdiction and business role.
Cosmetic Documentation: Compare the Four Documents
| Document | Main question it answers | Identity to check | What it cannot establish alone |
|---|---|---|---|
| COA: Certificate of Analysis | What did the stated testing find for this batch or sample? | Material or finished product, batch/sample number, specification | Complete safety, every claim, or conformity of another batch |
| SDS: Safety Data Sheet | What hazards and handling measures apply in the relevant supply/workplace context? | Substance or mixture, supplier, revision and intended use | Batch acceptance, full formula or cosmetic market authorization |
| Ingredient declaration, often called an INCI list | Which ingredient names belong on this market’s label? | Formula version, market, artwork and product variant | Exact percentages, ingredient authorization or finished-product safety |
| PIF: Product Information File | Is the EU product dossier assembled and accessible? | Exact product, responsible person and current supporting records | An automatic approval, or fulfilment of every other market’s rules |
These distinctions follow the different scopes of OSHA hazard communication, EU ingredient naming and the EU Cosmetics Regulation. The table is a purchasing aid, not a universal document checklist.
COA: Check the Batch and the Scope of Testing
A useful COA connects a named material or product to a particular batch or sample and reports the stated analytical results. FDA’s cosmetics inspection checklist discusses testing raw materials, in-process samples and finished products against specifications, together with batch and laboratory records. It does not establish one universal finished-cosmetic COA format. FDA cosmetics GMP inspection checklist
For procurement, agree the specification before asking whether the document says “pass.” Check:
- Product or material code, batch number and sample identity.
- Test names, methods, acceptance limits, units and results.
- Sampling or testing dates and the specification revision.
- Issuing organization, authorization and any qualifications or omissions.
A moisturizer COA might report appearance, pH and selected microbiological results under the agreed specification. Those entries do not automatically substantiate a hydration claim, shelf life or packaging compatibility. Request the relevant supporting study separately and confirm which formula, packaging and conditions it covers.
Keep raw-material and finished-product evidence distinct. A preservative supplier’s COA describes that supplied material; it does not prove that the finished cream passed its release criteria. Likewise, a development sample result should not silently become evidence for every commercial batch.
Before shipment, reconcile the COA’s batch identity with the shipment records and delivered stock. When a supplier reports only “conforms,” ask what was measured, what the acceptance rule was and whether more detailed results are available. Define handling of missing results and deviations in the quality agreement.

SDS: Assess Applicability Before Requesting a Generic Sheet
An SDS addresses chemical hazards and protective measures. OSHA’s standard exempts cosmetics packaged for consumer retail sale and cosmetics intended for employees’ personal consumption at work. This full-scope exemption is different from the standard’s separate exemption from its labelling requirements for certain FDA-regulated products. OSHA, 29 CFR 1910.1200(b)(5)–(6)
Hazardous bulk supplies intended for repackaging can remain covered. OSHA has specifically explained that bulk repackaging does not qualify merely because the eventual product will be used personally. OSHA bulk-supply interpretation
For the EU, REACH Article 2(6)(b) excludes cosmetic mixtures in their finished state, intended for final users, from Title IV supply-chain information provisions. That does not make the same conclusion appropriate for their raw materials. REACH Article 2
Practically, first identify whether the request concerns a fragrance concentrate, bulk formulation or finished retail product. Then confirm the market, use and reason for the request. An SDS for a raw ingredient should not be relabelled as the finished product’s SDS.
If a logistics provider or customer asks for an SDS, obtain its exact requirement and have the supplier assess the correct document. Separate that commercial request from the conclusion that an SDS is legally mandatory. ECHA explains that SDSs convey substance/mixture properties, hazards and handling information; they are not product-performance certificates. ECHA SDS overview
INCI: Align Ingredient Names, Formula and Artwork
INCI is a nomenclature system, not a certificate. EU ingredient labelling uses the Commission’s common ingredient names, taking account of INCI. The glossary does not authorize ingredients for unrestricted use. European Commission ingredient glossary
For an October 2026 review, note that Decision (EU) 2025/1175 applies from July 30, 2026 and replaces Decision 2022/677. Avoid treating an old supplier template as proof that current naming was checked. Decision (EU) 2025/1175
CosIng also states that an ingredient’s appearance in its inventory does not establish approval for cosmetic use. Assess applicable restrictions and intended use separately. European Commission CosIng explanation
A label ingredient declaration and a quantitative formula have different audiences. The declaration communicates names under the relevant labelling rules. The quantitative formula provides composition information needed for technical assessment. U.S. ingredient declarations follow FDA naming and ordering rules, including specific exceptions; ingredient percentages generally need not appear on the label. FDA Cosmetics Labeling Guide
During artwork review, compare the approved formula version with the declaration, then check every packaging panel and digital proof. Pay particular attention to premixes, fragrance, colour variants and supplier changes. Do not assume a trade-name ingredient corresponds to a single declaration entry.
Set controlled access for confidential formula information. Where the manufacturer supplies technical composition directly to an assessor, record who receives it and how updates will reach them. Confidentiality should be planned before the launch deadline.

PIF and CPSR: Assign Responsibility and Access
Under EU Article 11, the responsible person keeps the PIF for ten years after the last batch was placed on the market. It includes product identification, the CPSR, manufacturing method and GMP statement, appropriate claims evidence, and relevant animal-testing data. It must be updated as necessary and accessible to authorities at the responsible person’s labelled address. Article 10 requires a qualified safety assessment before placement on the market. EU Cosmetics Regulation, Articles 10–11
The CPSR is part of the PIF. It is not another name for the whole file. A folder containing an ingredient list, SDS and COA does not satisfy every dossier requirement simply because someone renames it “PIF.”
From the manufacturing side, agree which records will be supplied, who commissions the assessment, and who maintains the completed dossier. The responsible person’s legal duties and the commercial ownership of formula information are separate questions. Address confidentiality, access, updates and handover in the contract.
Use an index showing each document’s product identifier, version, holder and review status. A useful readiness check is whether the responsible person can retrieve the current evidence without relying on an unavailable sales contact. Test that access before launch and after changing suppliers or service providers.

Build a Cosmetic Documentation Request Around Decisions
Start with one product identity record: marketed name, product code, formula version, packaging version, intended use, claims and destination markets. Attach that record to the request so both sides understand what evidence is being discussed.
Use the following checkpoints as a proposed project workflow:
| Checkpoint | Manufacturer–buyer action | Decision before proceeding |
|---|---|---|
| Before quotation | Define markets, formula/packaging scope, claims and document responsibilities | Which evidence exists, and which work must be commissioned? |
| Before formula approval | Review available technical information and assessment requirements | Are gaps or changes likely to affect development? |
| Before artwork approval | Reconcile declaration, warnings and product identity with current records | Does the reviewed proof match the agreed product? |
| Before production/shipment | Confirm specifications, batch evidence and agreed release process | Are the required results complete and tied to the shipment? |
| After a change | Review formula, supplier, packaging, use or claim changes | Which documents and assessments need revision? |
For manufacturer coordination, use a defined scope for compliance documentation support. Clarify deliverables, responsible parties and access arrangements instead of relying on a general promise of “all certificates included.” The cosmetic manufacturer RFQ template provides related purchasing context.
Consider a brand ordering the same cream in a jar and a pump. The ingredient declaration may be shared if the formula is identical, while packaging-related supporting evidence needs review for each presentation. Flag the difference early rather than discovering it during artwork or dossier sign-off. This is a project-planning example, not a universal testing prescription.
Costs, Timing and Common Documentation Risks
Document pricing and timing are scope-dependent. Request an itemized quotation distinguishing existing records, new testing, assessment, translation, dossier assembly and later revisions. A quotation should state what samples or information are needed, who supplies them, and what event starts the quoted lead time.
Avoid scheduling from an assumed number of days. Formula or packaging changes can affect the scope already quoted. Ask how failed or inconclusive results, additional assessor questions and variant additions will be handled before committing to a launch date.
Common review errors include accepting a sample report for a different formula, filing an undated ingredient list, treating a raw-material SDS as finished-product evidence, and keeping records under a marketing name that differs from production codes. A simple cross-reference register helps reveal these mismatches.
Another risk is requesting an “FDA approval certificate” for ordinary cosmetic registration. FDA’s September 9, 2026 clarification states that registration/listing is not approval and that FDA does not issue documents verifying those registrations, listings or exemptions. FDA registration-certificate clarification
U.S. responsibilities also include maintaining adequate safety-substantiation records; FDA does not prescribe a single universal test battery. These duties should not be reduced to possessing an EU-style folder. FDA MoCRA overview. The related MoCRA cosmetics guide explains the U.S. workflow, while the Insights hub connects wider manufacturing topics.
Frequently Asked Questions
Does every cosmetic need all four documents?
No universal four-document rule applies. Establish the market and business role, then determine applicable dossier, labelling, safety and handling duties. Add contractual quality evidence where needed. Record the reason for each requested document.
Can an SDS replace a COA?
No. Hazard and handling information does not report acceptance of your particular batch. If the purchasing decision depends on a test result, request evidence tied to the correct batch or sample and specification.
Is an INCI list the complete formula?
No. A declaration supplies ingredient names under labelling rules; it ordinarily does not provide all quantitative technical information. Agree a secure route for the assessor or technical reviewer to receive the necessary composition data.
Can the factory prepare the PIF?
A manufacturer may help assemble supporting information under the agreed scope. Confirm the responsible person, assessor and document holder, and ensure access and updates work in practice. Preparing files does not by itself settle regulatory responsibility.
When should a brand request the documents?
Define the package at quotation stage, review formula-related records during development, reconcile labels before artwork approval, and check batch evidence before agreed release. Request updates when product or supply-chain changes affect the evidence.
For a product-specific manufacturing discussion, contact INHI with your target markets, product brief, proposed claims and current document list so the required support can be scoped.
Sources and References
- FDA cosmetics GMP inspection checklist
- OSHA Hazard Communication standard and bulk-cosmetics interpretation
- EU Cosmetics Regulation: Articles 10–11
- REACH Article 2: finished-product scope and ECHA safety data sheets
- European Commission ingredient glossary and Decision (EU) 2025/1175
- European Commission CosIng
- FDA Cosmetics Labeling Guide
- FDA MoCRA overview and September 2026 registration-certificate clarification